Share

Regulation and Products

We are working to ensure the law granting the U.S. Food and Drug Administration (FDA) the authority to regulate all tobacco products, including cigarettes, e-cigarettes, cigars and hookah is fully leveraged to protect children and adults.  

Regulation and Products Resources:

The Family Smoking Prevention and Tobacco Control Act (TCA) requires manufacturers of all new tobacco products to submit an application to the Food and Drug Administration’s Center for Tobacco Products (CTP) for premarket review to prove that the sale of their product is “appropriate for the protection of public health” prior to going on to the market. This is one of the most important provisions of the TCA, and was intended to prevent new, harmful tobacco products from ever being sold. Unfortunately, the premarket review of all new tobacco products has never taken full effect due to lack of enforcement by the agency, the tobacco industry continuing to sell new products without CTP authorization and implementation disruptions.

The Family Smoking Prevention and Tobacco Control Act (TCA) prohibits tobacco manufacturers from using misleading descriptors about their products and requires a substantive scientific review by the Food and Drug Administration's Center for Tobacco Products prior to using any "modified risk" claim. This is one of the most important provisions of the TCA as it directly addresses the tobacco industry's deceptive marketing practices about the harm of its products.

In March 2026, FDA released the “Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk; Draft Guidance for Industry." Draft Guidance provides FDA's current thinking about the topic of the guidance. The undersigned public health, medical, civil righs and community organizations conclude that the Draft Guidance fails to recognize the well-established history of signficant variations in youth flavor preferences over time, often caused by regulatory decisions, and this fundamental flaw threatens to open the regulatory door to a wide array of FDA-authorized products that would appeal and be accessible to youth, without signficant countervailing health benefits to adults who smoke.

American Academy of Pediatrics, American Cancer Society Cancer Action Network, American Heart Association, American Lung Association, and Campaign for Tobacco-Free Kids
oppose orders authorizing this claim because Swedish Match has failed to meet the statutory standard for the following reasons:
1. FDA’s past authorizations of a similar claim for General Snus should not determine whether the pending applications for ZYN nicotine pouches are granted because the
Tobacco Control Act requires product-specific analyses.
2. Significant differences between ZYN and General Snus – in use rates, relevant toxicology, flavors, and marketing – clearly warrant different consideration.
3. The applicant’s reliance on the “Swedish experience” is misleading and of limited relevance.
4. The applicant did not submit sufficient data on consumer perception or behavior change related to the proposed modified risk claim and this specific product.

Big tobacco has a history of prioritizing corporate profits over people and communities burdened by tobacco-related illness and death. For decades, the tobacco industry has lied to specific communities and the public at large saying their products are not addictive, harmful or deadly. Tobacco manufacturers continue to create and flood the market with newly designed products they market as being less harmful and alternatives to quitting – a tactic that is not new.